Evidence map›Paper›PMID 38542374›Full record

ReviewInternational journal of molecular sciences2024

Impact of α-Globin Gene Expression and α-Globin Modifiers on the Phenotype of β-Thalassemia and Other Hemoglobinopathies: Implications for Patient Management.

Joanne Traeger-Synodinos, Christina Vrettou, Christalena Sofocleous, Matteo Zurlo, Alessia Finotti, Roberto Gambari, International Hemoglobinopathy Research Network (INHERENT)

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Joanne Traeger-SynodinosLaboratory of Medical Genetics, National and Kapodistrian University of Athens, St. Sophia's Children's Hospital, 11527 Athens, Greece.ORCID 0000-0002-1860-5628
Christina VrettouLaboratory of Medical Genetics, National and Kapodistrian University of Athens, St. Sophia's Children's Hospital, 11527 Athens, Greece.
Christalena SofocleousLaboratory of Medical Genetics, National and Kapodistrian University of Athens, St. Sophia's Children's Hospital, 11527 Athens, Greece.ORCID 0000-0002-3205-4287
Matteo ZurloDepartment of Life Sciences and Biotechnology, 40124 Ferrara, Italy.ORCID 0000-0002-6131-3727
Alessia FinottiDepartment of Life Sciences and Biotechnology, 40124 Ferrara, Italy.ORCID 0000-0002-7638-515X
Roberto GambariCenter "Chiara Gemmo and Elio Zago" for the Research on Thalassemia, Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0001-9205-6033
International Hemoglobinopathy Research Network (INHERENT)
National and Kapodistrian University of Athens · GRUniversity of Ferrara · IT

Funding

Wellcome TrustWellcome Trust Innovator Award 208872/Z/17/Z
6 · The paper itself

Abstract

In this short review, we presented and discussed studies on the expression of globin genes in β-thalassemia, focusing on the impact of α-globin gene expression and α-globin modifiers on the phenotype and clinical severity of β-thalassemia. We first discussed the impact of the excess of free α-globin on the phenotype of β-thalassemia. We then reviewed studies focusing on the expression of α-globin-stabilizing protein (AHSP), as a potential strategy of counteracting the effects of the excess of free α-globin on erythroid cells. Alternative processes controlling α-globin excess were also considered, including the activation of autophagy by β-thalassemia erythroid cells. Altogether, the studies reviewed herein are expected to have a potential impact on the management of patients with β-thalassemia and other hemoglobinopathies for which reduction in α-globin excess is clinically beneficial.

Indexed as

beta-ThalassemiaHemoglobinopathiesalpha-GlobinsBlood ProteinsGene ExpressionHumansMolecular ChaperonesPhenotypeAHSP protein, humanalpha-GlobinsBlood ProteinsMolecular Chaperonesautophagysickle cell diseaseα-globinα-globin-stabilizing proteinβ-thalassemia

Identifiers

PMID38542374
PMCPMC10969871
OpenAlexW4392897398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.